Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as VYD222 (pemivibart)
VYD222 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Cohort A VYD222 | EXPERIMENTAL | - |
| Cohort B VYD222 | EXPERIMENTAL | - |
| Cohort B Placebo | PLACEBO_COMPARATOR | - |
| Cohort 1 | EXPERIMENTAL | 10 total participants Cohort 1. 8 participants on VYD222 2 participants on placebo |
| Cohort 2 | EXPERIMENTAL | 10 total participants Cohort 2. 8 participants on VYD222 2 participants on placebo |
| Cohort 3 | EXPERIMENTAL | 10 total participants Cohort 3. 8 participants on VYD222 2 participants on placebo |
| Name | Type | Description |
|---|---|---|
| VYD222 (pemivibart) | DRUG | Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222. |
| Normal saline | DRUG | Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo. |
| VYD222 | DRUG | Monoclonal antibody |
| Placebo | OTHER | Matching Placebo |
Inclusion Criteria: * Is an adult aged ≥18 years or an adolescent aged 12 to \<18 years and weighs at least 40 kg at the time of Screening. * Tests negative for current SARS-CoV-2 infection by local antigen test or RT-PCR at the time of Screening. * For Cohort A, has significant immune compromise f...
Top 9 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | ibuzatrelvir, Nirmatrelvir/ ritonavir, BNT162b2/RIV |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Molnupiravir |
| Invivyd, Inc. | IVVD | 2 | PHASE3 | VYD2311 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Tradipitant |
| Moderna, Inc. | MRNA | 2 | PHASE2 | mRNA-1283, mRNA-1273 |
| ImmunityBio Inc | IBRX | 2 | PHASE2 | Nogapendekin alfa inbakicept |
| Traws Pharma, Inc. | TRAW | 1 | PHASE2 | Ratutrelvir |
| GeoVax Labs, Inc. | GOVX | 1 | PHASE2 | GEO-CM04S1 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE2 | Remdesivir |
VYD222 is being developed for the prevention of COVID-19 caused by SARS-CoV-2. It is intended for adults with immune compromise and for people aged 12 years or older who are at risk of exposure to SARS-CoV-2. It is an investigational product and has not been approved by the FDA.
VYD222 targets SARS-CoV-2, the virus that causes COVID-19. It is a monoclonal antibody designed to bind the virus, which places it in the antiviral antibody class of therapies. Its development focuses on preventing COVID-19 in people who are immune compromised or otherwise at risk of exposure.
VYD222 is being developed by Invivyd, Inc., which trades on the Nasdaq under the ticker IVVD. Invivyd is the sponsor of the clinical program studying the antibody for prevention of COVID-19 in immune compromised and at-risk populations.
VYD222 has completed a Phase 3 clinical trial and a Phase 1 clinical trial. It is an investigational therapy and is not FDA approved. The Phase 3 study evaluated prevention of COVID-19, while the Phase 1 study assessed safety, tolerability, and pharmacokinetics in healthy adult participants.
VYD222 has been studied in two completed trials. NCT06039449 was a Phase 3 trial of COVID-19 prevention in adults with immune compromise and participants aged 12 years or older at risk of SARS-CoV-2 exposure, enrolling 790 participants in the United States. NCT05791318 was a Phase 1 safety, tolerability, and pharmacokinetics study in 30 healthy adults in Australia.
Yes. VYD222 is also known as pemivibart, so the two names refer to the same monoclonal antibody candidate. Searches for either name lead to the same Invivyd, Inc. development program for prevention of COVID-19 in immune compromised and at-risk populations.